title: Incidence of intermediate syndrome in organophosphorous poisoning.
abstract: Seventy two patients admitted to the Intensive Care Unit following ingestion of organophosphorus compounds were studied prospectively with two different doses of pralidoxime (PAM). One group received 1 gm immediately after admission and no further PAM and the other group received infusion of PAM, 1 gm 8 hourly for four days (total 12 gms). The incidence of type II paralysis or intermediate syndrome was 47%. We observed a higher incidence in the 4 days of infusion of PAM group (61%) (20 patients) as compared to the single Bolus dose group (39%) (13 patients). Relative risk 1.48 (confidence interval = 0.9-2.4).
authors.affiliation: Department of Medicine, Christian Medical College & Hospital, Tamil Nadu.
authors.forename: J
authors.initials: J
authors.lastname: Samuel
authors.forename: K
authors.initials: K
authors.lastname: Thomas
authors.forename: L
authors.initials: L
authors.lastname: Jeyaseelan
authors.forename: J V
authors.initials: JV
authors.lastname: Peter
authors.forename: A M
authors.initials: AM
authors.lastname: Cherian
mesh_terms: D000328:Adult; D002801:Cholinesterase Reactivators / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D062787:Drug Overdose / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D062025:Organophosphate Poisoning; D010243:Paralysis / Q000139:chemically induced* / Q000188:drug therapy; D011220:Pralidoxime Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D012133:Respiratory Paralysis / Q000139:chemically induced* / Q000188:drug therapy; D013577:Syndrome
chemical_list: D002801:Cholinesterase Reactivators; D011220:Pralidoxime Compounds; C028797:pralidoxime